Rationale for diagnosing deficiency of ChEs and for applying exogenous HuChEs to the treatment of diseases

Medical Hypotheses

Volumn 70, Issue 1, 2008, Pages 43-51

  Shen, Zheng Xuan ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; ATOPIC DERMATITIS; AUTOCRINE EFFECT; BODY FLUID; CANCER; CELL ADHESION; CELL CONTACT; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SECRETION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CYTOSKELETON; ELECTRIC ACTIVITY; ENZYME DEFICIENCY; HUMAN; HUMAN CELL; IMMUNE FUNCTION TEST; JUXTACRINE SIGNALING; LOCOMOTION; MICROENVIRONMENT; PARACRINE SIGNALING; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SOMATIC CELL; SYMPTOMATOLOGY;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; CHOLINE O-ACETYLTRANSFERASE; CHOLINESTERASES; CHRONIC DISEASE; DEFICIENCY DISEASES; DERMATITIS, ATOPIC; HUMANS; MODELS, ANIMAL; NEOPLASMS; RECEPTORS, CHOLINERGIC; RISK FACTORS;

EID: 36348929834     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.04.035     Document Type: Article

References (72)

1. Rang H.P. The receptor concept: pharmacology's big idea. Br J Pharmacol 147 Suppl 1 (2006) S9-S16
2. Brown D.A. Acetylcholine. Br J Pharmacol 147 Suppl 1 (2006) S120-S126
3. Lockridge O., and Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology 21 1-2 (2000) 113-126
4. Shen Z.X. Brain cholinesterases: I. The clinico-histopathological and biochemical basis of Alzheimer's disease. Med Hyp 63 2 (2004) 285-297
5. Shen Z.X. Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease. Med Hyp 63 2 (2004) 308-321
6. Shen Z.X. Brain cholinesterases: III. Future perspectives of AD research and clinical practice. Med Hyp 63 2 (2004) 298-307
7. Tansey E.M. Henry Dale and the discovery of acetylcholine. C R Biol 329 5-6 (2006) 419-425
8. Wessler I., Kirkpatrick C.J., and Racke K. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther 77 1 (1998) 59-79
9. Wessler I., Kilbinger H., Bittinger F., et al. The non-neuronal cholinergic system in: expression, function and pathophysiology. Life Sci 72 18-19 (2003) 2055-2061
10. Hasselmo M.E., and McGaughy J. High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog Brain Res 145 (2004) 207-231
11. Kurzen H., Wessler I., Kirkpatrick C.J., et al. The non-neuronal cholinergic system of human skin. Horm Metab Res 39 2 (2007) 125-135
12. Zhou F.M., Wilson C., and Dani J.A. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 9 1 (2003) 23-36
13. Zimmerman G., and Soreq H. Termination and beyond: acetylcholinesterase as a modulator of synaptic transmission. Cell Tissue Res 326 2 (2006) 655-669
14. Nakahara T., Kawada T., Sugimachi M., et al. Cholinesterase affects dynamic transduction properties from vagal stimulation to heart rate. Am J Physiol 275 2 Pt 2 (1998) R541-R547
15. Kczewski N., Aztiria E., Gautam D., et al. Acetylcholine modulates cortical synaptic transmission via different muscarinic receptors, as studied with receptor knockout mice. J Physiol 566 Pt 3 (2005) 907-919
16. Page J.D., and Wilson I.B. Acetylcholinesterase: inhibition by tetranitromethane and arsenite. Binding of arsenite by tyrosine residues. J Biol Chem 260 3 (1985) 1475-1478
17. Page J.D., Wilson I.B., and Silman I. Butyrylcholinesterase: inhibition by arsenite, fluoride, and other ligands, cooperativity in binding. Mol Pharmacol 27 4 (1985) 437-443
18. Mel'nikova T.N., and Murav'eva L.I. Acetylcholinesterase and monoamine oxidase in various brain structures in chronic alcoholic intoxication. Zh Nevropatol Psikhiatr Im S S Korsakova 87 2 (1987) 235-237
19. Davis L., Britten J.J., and Morgan M. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia 52 3 (1997) 244-260
20. Weik M., Ravelli R.B., Kryger G., et al. Specific chemical and structural damage to proteins produced by synchrotron radiation. Proc Natl Acad Sci USA 97 2 (2000) 623-628
21. Zhou J.F., Zhou Y.H., Zhang L., et al. 3,4-Methylenedioxymethamphetamine (MDMA) abuse markedly inhibits acetylcholinesterase activity and induces severe oxidative damage and liperoxidative damage. Biomed Environ Sci 16 1 (2003) 53-61
22. Kaizer R.R., da Silva A.C., Morsch V.M., et al. Diet-induced changes in AChE activity after long-term exposure. Neurochem Res 29 12 (2004) 2251-2255
23. Hyatt J.L., Tsurkan L., Morton C.L., et al. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. Chem Biol Interact 157-158 (2005) 247-252
24. Kucukkilinc T., and Ozer I. Inhibition of human plasma cholinesterase by malachite green and related triarylmethane dyes: mechanistic implications. Arch Biochem Biophys 440 2 (2005) 118-122
25. Frasco M.F., Fournier D., Carvalho F., and Guilhermino L. Do metals inhibit acetylcholinesterase (AChE)? Implementation of assay conditions for the use of AChE activity as a biomarker of metal toxicity. Biomarkers 10 5 (2005) 360-375
26. Nunes B., Carvalho F., and Guilhermino L. Effects of widely used pharmaceuticals and a detergent on oxidative stress biomarkers of the crustacean Artemia parthenogenetica. Chemosphere 62 4 (2006) 581-594
27. Li B., Sedlacek M., Manoharan I., et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70 11 (2005) 1673-1684
28. Hasin Y., Avidan N., Bercovich D., et al. A paradigm for single nucleotide polymorphism analysis: the case of the acetylcholinesterase gene. Hum Mutat 24 5 (2004) 408-416
29. Krejci E. Cholinesterases: anchored enzymes in membranes and basal laminae. J Soc Biol 199 1 (2005) 55-60
30. Shapira Y.A., Sadeh M.E., Bergtraum M.P., et al. Three novel COLQ mutations and variation of phenotypic expressivity due to G240X. Neurology 8 4 (2002) 603-609
31. Peng S., Wuu J., Mufson E.J., and Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 63 6 (2004) 641-649
32. Counts S.E., and Mufson E.J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 64 4 (2005) 263-272
33. Elble R., Giacobini E., and Higgins C. Choline levels are increased in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 10 1 (1989) 45-50
34. Hock C., Heese K., Muller-Spahn F., et al. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology 54 10 (2000) 2009-2011
35. Herholz K., Weisenbach S., Kalbe E., et al. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 16 13 (2005) 1431-1434
36. von Bernhardi R., Alarcon R., Mezzano D., et al. Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 19 4 (2005) 204-212
37. http://www.medscape.com/viewarticle/530368.
38. Wessler I., Reinheimer T., Kilbinger H., et al. Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci 72 18-19 (2003) 2169-2172
39. Kawashima K., and Fujii T. Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci 9 (2004) 2063-2085
40. Kraunz K.S., McClean M.D., Nelson H.H., et al. Duration but not intensity of alcohol and tobacco exposure predicts p16INK4A homozygous deletion in head and neck squamous cell carcinoma. Cancer Res 66 8 (2006) 4512-4515
41. Searles Nielsen S., Mueller B.A., De Roos A.J., et al. Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1). Environ Health Perspect 113 7 (2005) 909-913
42. Shpagina L.A., Panacheva L.A., Potapenko A.T., et al. Epidemiologic and radiobiologic features of neoplasms in respiratory and gastrointestinal tracts among patients who had occupational contact with uranium. Med Tr Prom Ekol 11 (2005) 43-47
43. Williams R.D., Boros L.G., Kolanko C.J., et al. Chromosomal aberrations in human lymphocytes exposed to the anticholinesterase pesticide isofenphos with mechanisms of leukemogenesis. Leukemia Res 28 (2004) 947-958
44. Russo P., Catassi A., Cesario A., and Servent D. Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system. Curr Med Chem 13 29 (2006) 3493-3512
45. Kaniaris P., Fassoulaki A., Liarmakopoulou K., and Dermitzakis E. Serum cholinesterase levels in patients with cancer. Anesth Analg 58 2 (1979) 82-84
46. McQueen M.J. Clinical and analytical considerations in the utilization of cholinesterase measurements. Clin Chim Acta 237 1-2 (1995) 91-105
47. Gu S.Z., Zhao X.H., Quan P., et al. Alterations of serum cholinesterase in patients with gastric cancer. World J Gastroenterol 11 29 (2005) 4604-4606
48. Vidal C.J. Expression of cholinesterases in brain and non-brain tumours. Chem Biol Interact 157-158 (2005) 227-232
49. Martinez-Moreno P., Nieto-Ceron S., Torres-Lanzas J., et al. Cholinesterase activity of human lung tumours varies according to their histological classification. Carcinogenesis 27 3 (2006) 429-436
50. Bui J.M., and McCammon J.A. Acetylcholinesterase: pivotal roles of its long omega loop (Cys69-Cys96) in regulating substrate binding. Chem BiolInteract 157-158 (2005) 357-359
51. Montenegro M.F., Ruiz-Espejo F., Campoy F.J., et al. Cholinesterases are down-expressed in human colorectal carcinoma. Cell Mol Life Sci 63 18 (2006) 2162-2175
52. Bartha E., Szelenyi J.G., and Hollan S.R. Acetylcholinesterase (AchE) activity of lymphocytes in chronic lymphoid leukemia (CLL). Leuk Res 6 6 (1982) 861-864
53. Tarkowski M., Lutz W., and Birindelli S. The lymphocytic cholinergic system and its modulation by organophosphorus pesticides. Int J Occup Med Environ Health 17 3 (2004) 325-337
54. Fernandez H.L., Moreno R.D., and Inestrosa N.C. Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation. J Neurochem 66 4 (1996) 1335-1346
55. Parent A.S., Rasier G., Gerard A., et al. Early onset of puberty: tracking genetic and environmental factors. Horm Res 64 Suppl 2 (2005) 41-47
56. Østergaard D., Viby-Mogensen J., Rasmussen S.N., Gätke M.R., and Varin F. Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. Anesthesiology 102 6 (2005) 1124-1132
57. Pic L.C. Novel pharmacological approaches for the antagonism of neuromuscular blockade. AANA J 73 1 (2005) 37-40
58. Lockridge O, Schopfer LM, Winger G, Woods JH. Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys; a potential new therapeutic for protection against cocaine and nerve agent toxicity. J Med Chem Biol Radiol Def. 3:nihms5095.
59. Doctor B.P., and Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 157-158 (2005) 167-171
60. Cerasoli D.M., Griffiths E.M., Doctor B.P., et al. In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact 157-158 (2005) 363-365
61. Cohen O., Kronman C., Raveh L., et al. Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds. Mol Pharmacol 70 3 (2006) 1121-1131
62. Fischer S., Arad A., and Margalit R. Lipsome-formulated enzymes for organophosphate scavenging: butyrylcholinesterase and Demeton-S. Arch Biochem Biophys 434 1 (2005) 108-115
63. Muralidharan M., Soreq H., and Mor T.S. Characterizing pea acetylcholinesterase. Chem Biol Inter 157-158 (2005) 406-407
64. Hrabovska A., Duysen E.G., Sanders J.D., et al. Delivery of human acetylcholinesterase by adeno-associated virus to the acetylcholinesterase knockout mouse. Chem Biol Interact 157-158 (2005) 71-78
65. Ruberg M., Villageois A., Bonnet A.M., et al. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. J Neurol Neurosurg Psychiatry 50 5 (1987) 538-543
66. Ruberg M., Rieger F., Villageois A., et al. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res 362 1 (1986) 83-91
67. Straus S.E. Pharmacotherapy of chronic fatigue syndrome: another gallant attempt. JAMA 292 10 (2004) 1234-1235
68. Staskin D.R., and MacDiarmid S.A. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 119 3 Suppl 1 (2006) 9-15
69. Brading A.F. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 96 3 (2005) 441-442
70. Duysen EG, Li B, Darvesh S, Lockridge O. Sensitivity of butyrylcholinesterase Tknockout mice to (-)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicol doi10.1016/j.tox 2006.11.069.
71. Bytyqi A.H., Lockridge O., Duysen E., et al. Impaired formation of the inner retina in an AChE knockout mouse results in degeneration of all photoreceptors. Eur J Neurosci 20 11 (2004) 2953-2962
72. De Jaco A., Comoletti D., Kovarik Z., et al. A mutation liked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha, beta-hydrlase fold protein family. J Biol Chem 281 14 (2006) 9667-9676